{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:54:38Z","timestamp":1777859678687,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Selection of schizophrenia or bipolar disorder treatments is complicated by treatment-effect heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study assessed how clinicians\u2019 beliefs and health system\/ insurace policies impact choice of atypical antipsychotic agent in schizophrenia and bipolar disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional survey was conducted of members of the American College of Clinical Pharmacy and College of Psychiatric &amp; Neurologic Pharmacists. Beliefs regarding atypical antipsychotic effectiveness and safety, impact of comorbidity on drug selection, and factors influencing atypical antipsychotic therapy selection were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-four psychiatric pharmacists and 18 psychiatrists participated. Mean age was 39.6 years, 57.1% were female. Most clinicians (64.3%) believed medication effectiveness and safety equally important, while 26.2% believed safety and 9.4% believed effectiveness more important. The most important medication properties for schizophrenia were reducing positive symptoms (92.7%) and hospitalizations (87.8%) and for bipolar disorder were reducing manic episodes (87.8%), episode relapse (53.7%), and hospitalizations (53.7%). Agranulocytosis (78.1%), arrhythmias (70.7%), and extrapyramidal side effects (68.3%) were most concerning. Restrictions affected antipsychotic choice at 80.5% of sites and were believed to affect medication adherence (55.0%) and outcomes (53.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Efficacy and safety were considered equally important when choosing atypical antipsychotics. Formulary restrictions were perceived as impacting treatment choice and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190019854566","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:11:44Z","timestamp":1561507904000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders"],"prefix":"10.1177","volume":"34","author":[{"given":"Daniel R.","family":"Touchette","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy and the Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deval","family":"Gor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy and the Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy and the Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel R.","family":"Chennault","sequence":"additional","affiliation":[{"name":"American College of Clinical Pharmacy Research Institute, Lenexa, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy S.","family":"Ng-Mak","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc, Marlborough, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc, Marlborough, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Ellingrod","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"bibr1-0897190019854566","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10278"},{"key":"bibr2-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"bibr3-0897190019854566","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v09n0405"},{"key":"bibr4-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.1737"},{"key":"bibr5-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-20"},{"key":"bibr6-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.133"},{"key":"bibr7-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1002\/gps.862"},{"key":"bibr8-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00498-X"},{"key":"bibr9-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(88)90203-1"},{"key":"bibr10-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7309.378"},{"key":"bibr11-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370070095014"},{"key":"bibr12-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(89)90252-9"},{"issue":"11","key":"bibr13-0897190019854566","first-page":"1891","volume":"39","author":"Segal R","year":"1982","journal-title":"Am J Hosp Pharm"},{"key":"bibr14-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198508000-00004"},{"key":"bibr15-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198203000-00004"},{"key":"bibr16-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002400514"},{"key":"bibr17-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002400415"},{"key":"bibr18-0897190019854566","unstructured":"Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. American Psychiatric Association. 2010. Accessed June 2, 2019. http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/schizophrenia.pdf"},{"key":"bibr19-0897190019854566","unstructured":"Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd ed. American Psychiatric Association. 2002. Accessed June 2, 2019. http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/bipolar.pdf"},{"key":"bibr20-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.09.018"},{"key":"bibr21-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.01.014"},{"key":"bibr22-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11010039"},{"key":"bibr23-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"bibr24-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"bibr25-0897190019854566","unstructured":"McDonagh M, Peterson K, Carson S, et al. Drug class review: atypical antipsychotic drugs: final update 3 report. Portland, OR: Oregon Health & Science University 2010."},{"key":"bibr26-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1213-6"},{"key":"bibr27-0897190019854566","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S151561"},{"key":"bibr28-0897190019854566","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0116"},{"key":"bibr29-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"bibr30-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"bibr31-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.229"},{"key":"bibr32-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"bibr33-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.09.006"},{"key":"bibr34-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.27.3.w185"},{"key":"bibr35-0897190019854566","unstructured":"Anonymous. Medicaid Preferred Drug Lists (PDLs) for Mental Health and Substance Abuse. February 2012. Accessed June 2, 2019. http:\/\/www.ncsl.org\/documents\/health\/pdl-2-2012.pdf"},{"key":"bibr36-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.1.61"},{"key":"bibr37-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1438"},{"key":"bibr38-0897190019854566","unstructured":"Board of Pharamacy Specialties. Psychiatric Pharmacy. 2019. Accessed June 2, 2019. https:\/\/www.bpsweb.org\/bps-specialties\/psychiatric-pharmacy\/"},{"key":"bibr39-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D390"},{"key":"bibr40-0897190019854566","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1004"},{"key":"bibr41-0897190019854566","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08946"},{"key":"bibr42-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq042"},{"issue":"1","key":"bibr43-0897190019854566","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519010-00001","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"bibr44-0897190019854566","doi-asserted-by":"publisher","DOI":"10.2165\/11634500-000000000-00000"},{"issue":"3","key":"bibr45-0897190019854566","first-page":"35","volume":"25","author":"McCombs JS","year":"2004","journal-title":"Health Care Financ Rev"},{"key":"bibr46-0897190019854566","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2010.16.5.317"},{"key":"bibr47-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.06.008"},{"key":"bibr48-0897190019854566","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0041-7"},{"key":"bibr49-0897190019854566","doi-asserted-by":"publisher","DOI":"10.2217\/cer.12.8"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019854566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190019854566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019854566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:33Z","timestamp":1777509333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190019854566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/0897190019854566"],"URL":"https:\/\/doi.org\/10.1177\/0897190019854566","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]}}}